COMMUNIQUÉS West-GlobeNewswire

Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes
29/03/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) EMA to review sotagliflozin as potential treatment for type 1 diabetes Paris - March 29, 2018 - The European Medicines Agency (EMA) has accepted for review Sanofi [...]
Sanofi soumet à l'EMA le dossier de la sotagliflozine dans le traitement potentiel du diabète de type 1
29/03/2018
Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi soumet à l'EMA le dossier de la sotagliflozine dans le traitement potentiel du diabète de type 1 Paris - Le 29 mars 2018 - L'Agence européenne des [...]
Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018
29/03/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Source: Ablynx (Euronext Brussels and Nasdaq: ABLX) Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018 Prospectus [...]
Les Offres Publiques d'Acquisition annoncées précédemment par Sanofi en vue d'acquérir Ablynx seront lancées le 4 avril 2018
29/03/2018
Communiqué de presse Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Source: Ablynx (Euronext Brussels and Nasdaq: ABLX) Les Offres Publiques d'Acquisition annoncées précédemment par Sanofi en vue d'acquérir Ablynx seront [...]
PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018
29/03/2018
Prospectus approved by the FSMA on March 27, 2018 and to be published on April 3, 2018 Initial acceptance period will commence on April 4, 2018 and expire on May 4, 2018, subject to extension Paris, France and Ghent, [...]
MDxHealth (R): Denominator PR
29/03/2018
Press release Regulated information 29 March 2018, 7 a.m. CET MDxHealth's New Share Capital Amount and New Number of Shares IRVINE, CA, and HERSTAL, BELGIUM - 29 March 2018 - MDxHealth SA (Euronext Brussels: MDXH) (" [...]
MDxHealth (R) : Denominator PR
29/03/2018
C ommuniqué de presse Information réglementée 29 mars 2018, 7h00 HEC Nouveau Montant du Capital Social et Nouveau Nombre d'Actions de MDxHealth IRVINE, CA, et HERSTAL (BELGIQUE) - le 29 mars 2018 - MDxHealth SA ( [...]
Addex Sucessfully Raises CHF40 million in Capital Increase
29/03/2018
Geneva, Switzerland, 29 March 2018 - Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorders, announced today that the company has successfully completed its [...]
Kiadis Pharma to announce Annual Results for the year ended December 31, 2017
29/03/2018
Kiadis Pharma to announce Annual Results for the year ended December 31, 2017 Amsterdam, The Netherlands, March 29, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: KDS) , a [...]
Lexicon Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application (MAA) for Sotagliflozin to Treat Adults With Type 1 Diabetes
29/03/2018
THE WOODLANDS, Texas, March 29, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA [...]
VIFOR PHARMA TO PROPOSE JACQUES THEURILLAT AS BOARD MEMBER
29/03/2018
Jacques Theurillat to be proposed to Annual Shareholder Meeting for appointment to Board Marc de Garidel will not stand for re-election All other members of the Board of Directors will stand for re-election VIFOR PHARMA [...]
Tower One Announces Extension of Warrant Incentive Program
29/03/2018
VANCOUVER, B.C., March 29, 2018 (GLOBE NEWSWIRE) -- Canada Tower One Wireless Corp (CSE:TO) (OTCMKTS:TOWTF) (Frankfurt: A2DKQ4 ) (“Tower One” or the “Company ”) announces, further to its news release dated January 9, [...]
Unum Therapeutics Announces Pricing of Initial Public Offering
29/03/2018
CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX ) (“Unum Therapeutics”), a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy products [...]
Sorrento Therapeutics Chairman/CEO update to stockholders
29/03/2018
SAN DIEGO, March 28, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ) Dear Sorrento Stockholders, Despite a recent short seller opinion piece aimed at undermining the credibility of Sorrento and its [...]
MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy
29/03/2018
LA JOLLA, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV ) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875 [...]
Mesoblast Phase 3 Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment
29/03/2018
NEW YORK and MELBOURNE, Australia, March 28, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (Nasdaq: MESO ) today announced that enrollment has completed in the Phase 3 trial evaluating a single intra-discal [...]
Arbutus to Present HBV Data at 2018 EASL Liver Meeting
28/03/2018
VANCOUVER, British Columbia and WARMINSTER, Pa., March 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today [...]
Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018
28/03/2018
DURHAM, N.C., March 28, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ: ARGS ), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the [...]
Altimmune Announces Financial Results for the Year Ended December 31, 2017 and Provides Corporate Update
28/03/2018
Conference call and webcast scheduled for tomorrow, March 29 at 8:30am ET GAITHERSBURG, Md., March 28, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT ), a clinical-stage immunotherapeutics company, today [...]

Pages